Comparison · NCT05576051-8923d4e6
All TNFi Initiators Combination vs Tofacitinib Initiators Combination: Number of Participants With mACR20 at 6 Months for Tofacitinib Combination With MTX vs TNFi Combination With MTX
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. All TNFi Initiators Combination vs Tofacitinib Initiators Combination: Number of Participants With mACR20 at 6 Months for Tofacitinib Combination With MTX vs TNFi Combination With MTX. Trial comparisons, record NCT05576051-8923d4e6. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05576051-8923d4e6
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.305 | 0.291 | 0.319 | wilson | |
| Risk in group 2 | 0.211 | 0.14 | 0.306 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0939 | -0.00237 | 0.167 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.44 | 0.966 | 2.16 | log | |
| Odds ratio, group 1 over group 2 | 1.64 | 0.984 | 2.73 | log | |
| Number needed to treat, for one more participant with the outcome on All TNFi Initiators Combination than on Tofacitinib Initiators Combination | 10.6 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | All TNFi Initiators Combination | Participants diagnosed with RA, enrolled in Corrona RA registry who initiated TNFi initiators treatment with combination of MTX were included in this reporting group. Data was collected for this study from 4-Jun-2015. | 1,224 | 4,013 | OG000 |
| Group 2 | Tofacitinib Initiators Combination | Participants diagnosed with RA, enrolled in Corrona RA registry who initiated Tofacitinib initiators treatment with combination of MTX were included in this reporting group. Data was collected for this study from 4-Jun-2015. | 19 | 90 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With mACR20 at 6 Months for Tofacitinib Combination With MTX vs TNFi Combination With MTX
- Description
mACR20 response: \>= 20 percent (%) improvement in tender and swollen joint count and 20% improvement in 2 of the following 4 criteria: 1) participant assessment of pain (scored from 0 to 100, higher scores indicated worsened pain) ; 2) participant global assessment of disease activity (scored from 0 to 100, higher scores indicated worsened condition); 3) physician global assessment of disease activity (scored from 0 to 100, higher scores indicated worsened condition); 4) self-assessed disability index of the mHAQ (scored from 0 to 3, higher scores indicated worsened function).
- Time frame
- At month 6 follow up visit
- Population
Analysis population included all eligible participants whose medical records were retrieved and observed in this study. Here, Overall number of Participants Analyzed signifies number of participants evaluable for this outcome measure.
Source ClinicalTrials.gov
Trial
- Title
To Estimate the Efficacy of Treatment With TNFi as Monotherapy or Combination Therapy With MTX and Compare and Contrast Efficacy With Tofacitinib as Monotherapy and Combination Therapy in a Real World Setting.
- NCT number
- NCT05576051
- Phases
- Conditions
- Rheumatoid Arthritis
- Interventions
- patterns of use of combination therapy and monotherapy
- Lead sponsor
- Pfizer
- Results first posted
- 2025-12-23
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT05576051?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT05576051-8923d4e6